Delivery Order SPE2DB25D2204-SPE2DB25FTGUF
- Not listed
- On July 29, 2025, the Defense Logistics Agency awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for INGREZZA 80 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of August 19, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,049.61 for INGREZZA 60 mg capsules (30-count units) on July 21, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from the vendor's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for the supply of INGREZZA 80 mg capsules (30-count) on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order represents a non-competitive set-aside and will be performed at the contractor's location in Conshohocken, Pennsylvania. INGREZZA is a neurological medication used to treat tardive dyskinesia, a movement disorder associated with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,027.70 to AmerisourceBergen Drug Corp for the supply of INGREZZA 80 MG capsules (30-count packaging) with an ultimate completion date of August 19, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the prime contractor. The place of performance is located in Conshohocken, Pennsylvania, the headquarters location of AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency awarded a $3,676.12 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ingrezza 40 mg capsules (30-count units). The contract, which is not set-aside, carries a firm fixed price structure with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This award represents a child contract under...
- This is a $3,676.12 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of INGREZZA 40 MG CAPSULE 30S, a prescription medication, with a performance period through July 23, 2025. The contract is not set-aside and was competitively awarded. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
- This is a $3,553.31 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of INGREZZA 40 MG CAPSULE 30S, a prescription medication. The order has an ultimate completion date of March 14, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,676.12 firm fixed-price delivery order is for the supply of INGREZZA 40 MG CAPSULE 30S, a pharmaceutical product. The contract has an ultimate completion date of March 17, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply 4563920336 - INGREZZA 80 MG CAPSULE 30S. This $3,893.15 order, awarded on March 11, 2024, has an ultimate completion date of April 1, 2024. Amerisourcebergen Drug Corp, as the prime contractor, is the sole awardee on this delivery order, which is not associated with any set-aside designation. Amerisourcebergen Drug...
- The U.S. government's Defense Logistics Agency (DLA) Troop Support Medical awarded a $7,106.64 firm-fixed-price delivery order contract (SPE2DX15D3012|SPE2DX25F8DA2) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of 4,566,078,085 units of the pharmaceutical product INGREZZA 40 MG CAPSULE 30S, with a period of performance ending on November 1, 2024. This award is a part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGUFDelivery Order
The Defense Logistics Agency awarded a $3,676.12 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of INGREZZA 40 mg capsules (30-count units). This is a firm fixed-price contract with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive award. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. INGREZZA is a pharmaceutical treatment used in military and federal healthcare settings as part of broader neuropsychiatric treatment protocols. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As the prime contractor on this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a diverse portfolio of medications and medical commodities to support military healthcare programs and federal medical systems worldwide. The company's federal contracting history demonstrates consistent capability in delivering specialized pharmaceuticals and medical supplies through competitive procurement processes, supporting Defense Health Agency operations and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 7/28/25 |